Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 3/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 3/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw813893 SCHEMBL4559370 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL6219768 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL16439470 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL675586 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL675588 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| Gw813893 SCHEMBL23752149 | 1.00 | F10 (1.00) | F10F2KLKB1PLAT | |
| SCHEMBL4704233 | 0.89 | F10 (0.80) | F10F2KLKB1PLAT | |
| SCHEMBL4704238 | 0.89 | F10 (0.80) | F10F2KLKB1PLAT | |
| SCHEMBL6666834 | 0.86 | F10 (1.00) | F10F2KLKB1PLAT | |
| SCHEMBL4488532 | 0.86 | F10 (1.00) | F10F2KLKB1PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946219-B2 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2146705-B1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARM INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2586439-A1 | Combination therapy with a compound acting as a platelet ADP receptor inhibitor | Portola Pharmaceuticals, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20090048216-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | PORTOLA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048216-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | F10 192/4885F2 47/4885KLKB1 870/4885 |
| US-20120009172-A1 | INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR | P2RY12, P2RY11, P2RY13 | F10 192/4885F2 47/4885KLKB1 870/4885 |
| US-20080279845-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | MPL, P2RY4, P2RY1 | F10 472/4885F2 343/4885KLKB1 2951/4885 |
| US-20110033459-A1 | COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR | MPL, P2RY4, P2RY1 | F10 472/4885F2 343/4885KLKB1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.